The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin’s lymphoma who are candidates for up-front autologous stem cell transplantation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited. Methods: Consecutive patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP who underwent chemomobilization using HDC or DHAP plus granulocyte-colony stimulating factor (G-CSF) for up-front ASCT were enrolled from three institutions between 2004 and 2014. Results: Ninety-six patients (57 men) were included. Sixty-five patients (67.7%) received HDC; and 31 (32.3%), DHAP. The total CD34+ cells mobilized were significantly higher in patients receiving DHAP (16.1 vs. 6.1 × 106/kg, p = 0.001). More patients achieved successful mobilization with DHAP (CD34+ cells ≥ 5.0 × 106/kg) compared to HDC (87.1% vs. 61.5%, respectively; p = 0.011), particularly within the first two sessions of apheresis (64.5% vs. 32.3%, respectively; p = 0.003). Mobilization failure rate (CD34+ cells < 2.0 × 106/kg) was significantly higher in patients receiving HDC (20.0% vs. 3.2%, p = 0.032). On multivariate analysis, the DHAP regimen (odds ratio, 4.12; 95% confidence interval, 1.12 to 15.17) was an independent predictor of successful mobilization. During chemomobilization, patients receiving HDC experienced more episodes of febrile neutropenia compared to patients receiving DHAP (32.3% vs. 12.9%, p = 0.043). Conclusions: The DHAP regimen was associated with a significantly higher efficacy for stem cell mobilization and lower frequency of febrile neutropenia. Therefore, DHAP plus G-CSF is an effective for mobilization in patients with aggressive NHL who were candidates for up-front ASCT.
Abstract
Background/Aims: Data on dexamethasone, cytarabine, and cisplatin (DHAP) as a mobilization regimen, compared to high-dose cyclophosphamide (HDC), for up-front autologous stem cell transplantation (ASCT) in non-Hodgkin’s lymphoma (NHL) is limited. Methods: Consecutive patients with aggressive NHL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or rituximab-CHOP who underwent chemomobilization using HDC or DHAP plus granulocyte-colony stimulating factor (G-CSF) for up-front ASCT were enrolled from three institutions between 2004 and 2014. Results: Ninety-six patients (57 men) were included. Sixty-five patients (67.7%) received HDC; and 31 (32.3%), DHAP. The total CD34+ cells mobilized were significantly higher in patients receiving DHAP (16.1 vs. 6.1 × 106/kg, p = 0.001). More patients achieved successful mobilization with DHAP (CD34+ cells ≥ 5.0 × 106/kg) compared to HDC (87.1% vs. 61.5%, respectively; p = 0.011), particularly within the first two sessions of apheresis (64.5% vs. 32.3%, respectively; p = 0.003). Mobilization failure rate (CD34+ cells < 2.0 × 106/kg) was significantly higher in patients receiving HDC (20.0% vs. 3.2%, p = 0.032). On multivariate analysis, the DHAP regimen (odds ratio, 4.12; 95% confidence interval, 1.12 to 15.17) was an independent predictor of successful mobilization. During chemomobilization, patients receiving HDC experienced more episodes of febrile neutropenia compared to patients receiving DHAP (32.3% vs. 12.9%, p = 0.043). Conclusions: The DHAP regimen was associated with a significantly higher efficacy for stem cell mobilization and lower frequency of febrile neutropenia. Therefore, DHAP plus G-CSF is an effective for mobilization in patients with aggressive NHL who were candidates for up-front ASCT.
참고문헌 (32)
- Stiff PJ, "Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma", N Engl J Med, 369, pp.1681~1690 (2013)
- Villanueva ML, "The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma", Clin Adv Hematol Oncol, 4, pp.521~530 (2006)
- 이홍기, "R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma", Blood Research, 49(2), pp.107~114 (2014), 대한혈액학회
- Giralt S, "Optimizing autologous stem cell mobilization strategies to improve patient outcomes:consensus guidelines and recommendations", Biol Blood Marrow Transplant, 20, pp.295~308 (2014)
- Sanchez-Ortega I, "Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization", Bone Marrow Transplant, 50, pp.34~39 (2015)
- Wuchter P, "Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation", Biol Blood Marrow Transplant, 16, pp.490~499 (2010)
- Sung AD, "Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone", Bone Marrow Transplant, 48, pp.1444~1449 (2013)
- Narayanasami U, "Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation", Blood, 98, pp.2059~2064 (2001)
- Pusic I, "Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation", Biol Blood Marrow Transplant, 14, pp.1045~1056 (2008)
- Milone G, "G-CSF alone vs cyclophosphamide plus G-CSF in PBPC mobilization of patients with lymphoma: results depend on degree of previous pretreatment", Bone Marrow Transplant, 31, pp.747~754 (2003)
- Dazzi C, "Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin’s Lymphoma?", Leuk Lymphoma, 39, pp.301~310 (2000)
- Dingli D, "Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma", Clin Lymphoma Myeloma, 6, pp.384~388 (2006)
- Hyun SY, "High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma previously treated with CHOP-based chemotherapy:a study from the Consortium for Improving Survival of Lymphoma", Biol Blood Marrow Transplant, 20, pp.73~79 (2014)
- Pavone V, "Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin’s lymphoma", Bone Marrow Transplant, 29, pp.285~290 (2002)
- Pavone V, "Poor mobilization is an independent prognostic factor in patients with ma-lignant lymphomas treated by peripheral blood stem cell transplantation", Bone Marrow Transplant, 37, pp.719~724 (2006)
- 곽재용, "Treatment of Diffuse Large B Cell Lymphoma", The Korean Journal of Internal Medicine, 27(4), pp.369~377 (2012), 대한내과학회[DOI]
- Sehn LH, "Diffuse large B-cell lymphoma:optimizing outcome in the context of clinical and biologic heterogeneity", Blood, 125, pp.22~32 (2015)
- Vose J, "International peripheral T-cell and natural killer", T-cell lymphoma study: pathology findings and clinical outcomes, 2008, pp.26, 4124~4130
- Gertz MA, "Current status of stem cell mobilization", Br J Haematol, 150, pp.647~662 (2010)
- Gisselbrecht C, "Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma", J Clin Oncol, 30, pp.4462~4469 (2012)
- Philip T, "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma", N Engl J Med, 333, pp.1540~1545 (1995)
- Suh C, "Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000", Transfusion, 44, pp.1762~1768 (2004)
- Cheson BD, "Revised response criteria for malignant lymphoma", J Clin Oncol, 25, pp.579~586 (2007)
- Ford CD, "Effect of prior chemotherapy on hematopoietic stem cell mobilization", Bone Marrow Transplant, 33, pp.901~905 (2004)
- Jillella AP, "Infectious complications in patients receiving mobilization chemotherapy for autologous peripheral blood stem cell collection", J Hematother Stem Cell Res, 12, pp.155~160 (2003)
- Jin Seok Ahn, "High-dose Versus Low-dose Cyclophosphamide in Combination with G-CSF for Peripheral Blood Progenitor Cell Mobilization", The Korean Journal of Internal Medicine, 20(3), pp.224~231 (2005), 대한내과학회
- Damon L, "Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin’s lymphoma", Bone Marrow Transplant, 42, pp.649~657 (2008)
- Yoon DH, "Higher infused CD34+hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin’s lymphoma", Transfusion, 49, pp.1890~1900 (2009)
- Gordan LN, "Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin’s and non-Hodgkin’s Lymphoma", Bone Marrow Transplant, 31, pp.1009~1013 (2003)
- Sauter CS, "The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous stem cell transplant for hematologic malignancies", Leuk Lymphoma, 56, pp.1619~1625 (2015)
- Ketterer N, "High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation", Blood, 91, pp.3148~3155 (1998)
- Porrata LF, "Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma", Blood, 98, pp.579~585 (2001)